What is NodThera?
NodThera is a specialized biotechnology enterprise dedicated to the development of small-molecule inhibitors that target the NLRP3 inflammasome. By focusing on the root causes of chronic inflammation, the company aims to disrupt the current treatment landscape for a variety of systemic diseases. Their scientific methodology is rooted in rigorous evidence, positioning the firm as a frontrunner in the precision medicine sector. With a team of seasoned biotech innovators, NodThera is systematically building a portfolio of medicines designed to provide transformative outcomes for patients globally.
How much funding has NodThera raised?
NodThera has raised a total of $95M across 2 funding rounds:
Series A
$40M
Series B
$55M
Series A (2018): $40M with participation from 5AM Ventures, Epidarex Capital, Sofinnova Partners, and F-Prime Capital
Series B (2020): $55M led by Epidarex Capital, 5AM Ventures, F-Prime Capital, Novo Ventures, Sanofi Ventures, Cowen Healthcare Investments, and Sofinnova Partners
Key Investors in NodThera
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
Epidarex Capital
Epidarex is a transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs, utilizing deep scientific networks to create exceptional value.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability, acting as a hands-on company builder across the entire value chain.
What's next for NodThera?
With the recent influx of capital, NodThera is expected to prioritize the clinical validation of its lead candidates. The strategic roadmap likely involves expanding its internal research capabilities and accelerating the transition of its NLRP3-targeting therapies through regulatory milestones. As the company scales, it will continue to leverage its strong syndicate of life science investors to navigate the complexities of drug development and commercialization. The focus remains on establishing a robust clinical footprint that validates the therapeutic potential of its inflammasome-modulating platform in high-burden disease areas.
See full NodThera company page
